Efficacy of a single oral dose of 200 mg pramiconazole in vulvovaginal yeast infections: An exploratory phase IIa trial

Acta Dermato-Venereologica

Volumn 88, Issue 5, 2008, Pages 462-466

  Donders, Gilbert ^a   Ausma, Jannie ^b   Wouters, Luc ^b   Cauwenbergh, Geert ^c   Borgers, Marcel ^b,d   Janssens, Dirk ^e  

^a Femicare vzw   (Belgium)

^b Barrier Therapeutics nv   (Belgium)

^c Barrier Therapeutics Inc   (United States)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e Gynaecologische Dienst   (Belgium)

Author keywords

Candida; Phase IIa trial; Pramiconazole; Vulvovaginal yeast infection

Indexed keywords

AZOLINE; PRAMICONAZOLE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERADICATION THERAPY; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MICROSCOPY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; SCORING SYSTEM; SINGLE DRUG DOSE; SKIN IRRITATION; SYMPTOM; VAGINA MYCOSIS;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; CANDIDIASIS, VULVOVAGINAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MICROSCOPY; RECURRENCE; TRIAZOLES;

EID: 53349109646     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0494     Document Type: Article

References (19)

1. Guidance for Industry. Vulvovaginal candidiasis - developing antimicrobial drugs for treatment. Draft guidance. US Department of Health and Human Services, FDA, CDER, 1998.
2. De Punzio C, Garutti P, Mollica G, Nappi C, Piccoli R, Genazzani AR. Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double blind randomized study. Eur J Obst Gynecol Reprod Biol 2003; 106: 193-197.
3. Yule V. Treatment option: a patient's viewpoint. Finding from a pan-European survey. Int J Gynecol Obstet 1992; 37: 45-49.
4. Sobel JD. Treatment of vaginal Candida infections. Expert Opin Pharmacother 2002; 3: 1059-1065.
5. Odds FC. Genital candidiasis. Clin Exp Dermatol 1982; 7: 345-354.
6. Odds F, Ausma J, Van Gerven F, Woestenborghs F, Meerpoel L, Heeres J, et al. In vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrob Agents Chemother 2004; 48: 388-391.
7. Vanden Bossche H, Ausma J, Bohets H, Vermuyten K, Willemsens G, Marichal P, et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp. and Microsporum canis. Antimicrob Agents Chemother 2004; 48: 3272-3278.
8. Meerpoel L, Backx LJJ, Van der Veken LJE, Heeres J, Corens D, De Groot A, et al. Synthesis and in vitro and in vivo structure-activity relationship of novel antifungal triazoles for dermatology. J Med Chem 2005; 48: 2184-2193.
9. Faergemann J, Ausma J, Vandeplassche L, Borgers M. The efficacy of oral treatment with pramiconazole in Pityriasis versicolor: a phase IIa trial. Br J Dermatol 2007; 156: 1385-1387.
10. Degreef H, Heeres J, Borgers M. Antifungal azoles for skin disorders. Expert Opin Ther Patents 2006; 16: 1235-1253.
11. Decroix J, Ausma J, Cauwenbergh G, Borgers M, Wouters L. The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/ corporis: 2 exploratory phase IIa trials. Br J Dermatol 2008; e-pub january.
12. Faergemann J, Borgers M. The effect of ketoconazole and itraconazole on the filamentous form of Pityrosporum ovale. Acta Derm Venereol 1990; 70: 172-175.
13. Sanz-Sanz F and Hernanz P. Randomized comparative trial of three regimens of itraconazole for treatment of vaginal mycosis. Rev Infect Dis 1987; 9: S139-S142.
14. Woolley PD and Higgins SP. Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis. Br J Clin Pract 1995; 49: 65-66.
15. Urünsak M, Ilkit M, Evrüke, Urünsak I. Clinical and mycological efficacy of single-day oral treatment with itraconazole (400 mg) in acute vulvovaginal candidosis. Mycoses 2004; 47: 422-427.
16. Wesel S. Itraconazole; a single-day oral treatment for acute vulvovaginal candidosis. Br J Clin Pract Suppl 1990; 71: 77-80.
17. Cauwenbergh G, De Doncker P. The clinical use of itraconazole in superficial and deep mycosis. Recent trends in discovery, development and evaluation of antifungal agents. Fromtling RA, editor. J. R. Prous Science Publishers, S.A. 1987.
18. Tobin JM, Loo P, Granger SE. Treatment of vaginal candidosis; a comparative study of the efficacy and acceptability of itraconazole and clotrimazole. Genito-urin Med 1992; 68: 36-38.
19. Sobel JD, Brooker D, Stein GE, Thomason JL Wermeling DP, Bradley B, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Am J Obstet Gynecol 1995; 172: 1263-1268.